Attorney Docket No.: STI-201CN2 Group Art Unit: 1653

Examiner: G. Bugaisky

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10. (Cancelled).

11. (Currently Amended) A method for killing primary cancer cells from a patient, comprising obtaining said cells from said patient, contacting said cells with a verotoxin in vitro, such that said cells are killed, wherein said cells are Gb₃ positive.

Claims 12-13 (Cancelled).

- 14. (Previously Presented) The method of claim 11, wherein said patient is a human.
- (Previously Presented) The method of claim 11, wherein said verotoxin is 15. verotoxin 1.
- 16. (Previously Presented) The method of claim 11, wherein said verotoxin is verotoxin 2.
- 17. (Previously Presented) The method of claim 11, wherein said verotoxin is verotoxin 2c.
- (Previously Presented) The method of claim 11, wherein said cancer cells are 18. from a tumor.
- 19. (Previously Presented) The method of claim 18, wherein said tumor is a breast, ovarian, brain, or skin tumor.
- 20. (Previously Presented) The method of claim 11, wherein said cells are multidrug resistant.

Attorney Docket No.: STI-201CN2 Page 3
Examiner: G. Bugaisky Group Art Unit: 1653

21. (Previously Presented) A method for killing cancer cells from a patient, comprising obtaining said cells from said patient, contacting said cells with a verotoxin, such that said cells are killed, wherein said cells are Gb₃ positive and multidrug resistant.

- 22. (Previously Presented) The method of claim 21, wherein said cells are contacted with said verotoxin *in vitro*.
- 23. (Previously Presented) A method for killing Gb₃ positive cells from a breast, ovarian, brain, or skin tumor in a patient, comprising obtaining said cells from said patient, contacting said cells with a verotoxin, such that said cells are killed.
- 24. (Previously Presented) The method of claim 23, wherein said cells are contacted with said verotoxin *in vitro*.
- 25. (Previously Presented) The method of claim 23, wherein said cells are multidrug resistant.